Company news
Mindwalk Holdings Corp. (NASDAQ:HYFT) news
Mindwalk Holdings Corp. news releases on 6ix. Latest, Oct 6, 2026: MindWalk (NASDAQ: HYFT): Enterprise AI Has Found Its Ontology Layer. Biology Needs One…
Press releases & updates
MindWalk (NASDAQ: HYFT): Enterprise AI Has Found Its Ontology Layer. Biology Needs One Grounded in Biological Function
October 6, 2026
MindWalk Appoints Kim Remizowski to Board of Directors as Independent Director
October 1, 2026
MindWalk Appoints Kim Remizowski to Board of Directors as Independent Director
September 30, 2026
MindWalk Brings OpenFold3 into Production in Minutes with AMD Inference Microservices on Vultr Kubernetes Engine
September 21, 2026
MindWalk Reports 21% Revenue Growth and Gross Margin Expansion to 59% in Fiscal First Quarter 2027
September 14, 2026
MindWalk Lands Binding Commitment for US$30 Million Unsecured Credit Facility to Fund Biologics Programs and Commercial Expansion
September 14, 2026
MindWalk to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 10, 2026
MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2027 on September 14, 2026
September 8, 2026
MindWalk Showcases ReefIQ™ for AI Drug Discovery at AMD Advancing AI
July 22, 2026
MindWalk Holdings Corp. Reports Fiscal 2026 Results: Revenue Up 46% as the Company Completes Its Pivot to Bio-Native AI Infrastructure
July 22, 2026
MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2026 on July 22, 2026
July 13, 2026
MindWalk Holdings Corp. (NASDAQ: HYFT) Added to the Russell 3000E Index, Expanding Institutional Investment Opportunity
July 6, 2026
MindWalk (NASDAQ: HYFT) Files Patent for High-Dimensional Biological Data Architecture Powering AI Drug Discovery
July 1, 2026
MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery
June 12, 2026
MindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ, a Biological Context Layer for AI Drug Discovery
June 11, 2026
MindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery
June 10, 2026
MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across Two Independent Campaigns
June 2, 2026
MindWalk Holdings Deploys Pandemic Response Platform via HYFT® Technology as Ebola and Hantavirus Outbreaks Expose the Limits of Strain-Specific Coverage
May 26, 2026
The Biology Came First.
May 18, 2026
MindWalk : Third Quarter 2026 Transcript
March 16, 2026
MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results
March 11, 2026
MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era
March 5, 2026
MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026
March 2, 2026
MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics
January 27, 2026
MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease
January 13, 2026
REPEAT/MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight
January 12, 2026
MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight
January 8, 2026
MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline
December 14, 2025
MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2026 on December 15, 2025
December 8, 2025
MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025
November 13, 2025
MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy
October 20, 2025
MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion
October 14, 2025
MindWalk Announces Share Repurchase Program
October 8, 2025
MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity
September 21, 2025
MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet
September 14, 2025
MindWalk to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2026 on September 15, 2025
September 10, 2025
IPA’s Subsidiary, BioStrand, Provides an Update on LENSai™
October 24, 2023